Skip to main content

Table 3 Treatment-dependent difference in core outcome measures used to assess disease activity in rheumatoid arthritis (RA)

From: Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study

Parameter, % change from baseline to week 8

ACR50 Patients

Tocilizumab

Methotrexate

Responders

Non-Responders

Responders

Non-Responders

DAS28% mean (CI-95%)

− 54.7 (− 60.1 to −49.3)

−30.0 (− 33.0 to − 27.0)

−46.4 (− 52.1 to − 40.7)

−12.8 (− 15.7 to − 10.1)

SJC, % mean (CI-95%)

− 78.4 (− 83.8 to − 73.0)

−29.7 (− 37.6 to − 21.7)

−80.7 (− 89.0 to − 72.5)

−22.8 (− 32.1 to − 13.6)

TJC, % mean (CI-95%)

−76.3 (− 80.7 to − 72.0)

−25.8 (− 34.1 to − 17.5)

−73.6 (− 81.4 to − 65.8)

− 22.1 (− 30.1 to − 14.2)

VAS Pain, % mean (CI-95%)

−7.7 (− 35.2 to 19.9)

−10.5 (− 28.5 to 7.5)

−40.8 (− 68.3 to − 13.4)

−22.8 (− 36.6 to − 8.9)

  1. Table represent mean percentage change from baseline to week 8 for each respective parameter. DAS28 28-Joint Disease Activity Score, TJC tender joint count, SJC swollen joint count, VAS Pain visual analogue scale pain